John Yuen

Prof. John Yuen

Stony Brook University
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2021 in eLife
Verified
Journal Article
Open access
LNLuke M Noble
Luke M Noble
JYJohn Yuen
John Yuen
LSLewis Stevens
Lewis Stevens
NMNicolas Moya
Nicolas Moya
RPRiaad Persaud
Riaad Persaud
MRMatthew V Rockman
Matthew V Rockman
Mating systems have profound effects on genetic diversity and compatibility. The convergent evolution of self-fertilization in threeCaenorhabditisspecies provides a powerful lens to examine causes and consequences of mating system transitions. Among the selfers,Caenorhabditis tropicalisis the least genetically diverse and most afflicted by outbreeding depression. We generated a chromosomal-scale genome forC. tropicalisand surveyed global diversity. Population structure is very strong, and islands of extreme divergence punctuate a genomic background that is highly homogeneous around the globe. Outbreeding depression in the laboratory is caused largely by multiple Medea-like elements, genetically consistent with maternal toxin/zygotic antidote systems. Loci with Medea activity harbor novel and duplicated genes, and their activity is modified by mito-nuclear background. Segregating Medea elements dramatically reduce fitness, and simulations show that selfing limits their spread. Frequent selfing inC. tropicalismay therefore be a strategy to avoid Medea-mediated outbreeding depression.

Verified
Journal Article
Open access
PDF file
GHGa-Ram Hwang
Ga-Ram Hwang
JYJohn Yuen
John Yuen
JJJingfang Ju
Jingfang Ju
Resistance to cancer treatment is one of the major challenges currently faced when treating gastrointestinal (GI) cancers. A major contributing factor to this resistance is the presence of cancer stem cells (CSCs) in GI cancers (e.g., colorectal, pancreatic, gastric, liver cancer). Non-coding RNAs, such as microRNAs (miRNAs), have been found to regulate several key targets that are responsible for cancer stemness, and function as oncogenic miRNAs (oncomiRs) or tumor suppressor miRNAs. As a result, several miRNAs have been found to alter, or be altered by, the expression of CSC-defining markers and their related pathways. These miRNAs can be utilized to affect stemness in multiple ways, including directly targeting CSCs and enhancing the efficacy of cancer therapeutics. This review highlights current studies regarding the roles of miRNAs in GI CSCs, and efforts towards the development of cancer therapeutics.

5 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJohn Yuen
John Yuen
AMAmy C. Marshilok
Amy C. Marshilok
PBPeter Todd Benziger
Peter Todd Benziger
SYShan Yan
Shan Yan
JCJeronimo Cello
Jeronimo Cello
KSKenneth R. Shroyer Shroyer
Kenneth R. Shroyer Shroyer
In times of crisis, including the current COVID-19 pandemic, the supply chain of filtering facepiece respirators, such as N95 respirators, are disrupted. To combat shortages of N95 respirators, many institutions were forced to decontaminate and reuse respirators. While several reports have evaluated the impact on filtration as a measurement of preservation of respirator function after decontamination, the equally important fact of maintaining proper fit to the users’ face has been understudied. In the current study, we demonstrate the complete inactivation of SARS-CoV-2 and preservation of fit test performance of N95 respirators following treatment with dry heat. We apply scanning electron microscopy with energy dispersive X-ray spectroscopy (SEM/EDS), X-ray diffraction (XRD) measurements, Raman spectroscopy, and contact angle measurements to analyze filter material changes as a consequence of different decontamination treatments. We further compared the integrity of the respirator after autoclaving versus dry heat treatment via quantitative fit testing and found that autoclaving, but not dry heat, causes the fit of the respirator onto the users face to fail, thereby rendering the decontaminated respirator unusable. Our findings highlight the importance to account for both efficacy of disinfection and mask fit when reprocessing respirators to for clinical redeployment.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
GHGa-Ram Hwang
Ga-Ram Hwang
JYJohn Yuen
John Yuen
HFHannah Farley
Hannah Farley
JJJingfang Ju
Jingfang Ju
Lung cancer is the leading cancer type of cancer-related deaths in the U.S., with non-small cell lung cancer (NSCLC) accounting for a majority of cases. Despite innovations in cancer therapeutics, due to resistance to these therapeutics, the 5-year survival rate for patients with metastatic lung cancer has remained poor. As a result, there is an urgent need to develop new and effective therapeutics, including the study of RNA-based therapeutics. Previous studies from our laboratory have shown that 5-fluorouracil (5-FU) modified tumor suppressor miRNAs significantly enhance the therapeutic efficacy, stability, and deliverability of miRNAs in colorectal cancer (CRC) and pancreatic cancer. In this study, we have characterized the therapeutic potential of miR-129 modified with 5-FU (5-FU-miR-129) in non-small cell lung cancer in vitro via Annexin V staining, cell cycle analysis, and Western Blot. 5-FU-miR-129’s therapeutic potential was also assessed in vivo via IVIS imaging of NSCLC xenografts. We have demonstrated that 5-FU-miR-129 can induce apoptosis (7.2-fold in A549 and 2.9-fold in Calu-1) and cell cycle arrest (12.7-fold change in G1/S phase ratio in A549) in NSCLC in vitro. Furthermore, 5-FU-miR-129 has been found to retain target specificity by downregulating miR-129 targets BCL2 and HMGB1 in a cell line-dependent manner. As was observed in previous studies, we have also demonstrated the ability of 5-FU-miR-129 to be delivered in cancer cells without the use of a transfection vehicle in vitro. Finally, we were also able to demonstrate the therapeutic potential of 5-FU-miR-129 in inhibiting NSCLC tumor growth in vivo, as seen by a significantly decreased change in tumor growth by 37 days post-treatment in the 5-FU-miR-129 treated group compared to the negative control group (79.8% reduction in tumor growth). In addition, we observed a significant increase in survival probability and a reduced hazard ratio in mice treated5-FU-miR-129 when compared to the negative control group. Furthermore, we did not observe any visible side effects (hair loss) of mice treated with 5-FU-miR-129 compared to chemotherapeutic drugs 5-FU and gemcitabine (Gem). 5-FU-miR-129’s therapeutic potential in NSCLC further demonstrates the potential for modified miRNAs as a platform technology in cancer therapeutics. Citation Format: Ga-Ram Hwang, John G. Yuen, Hannah Farley, Jingfang Ju. Development of a 5-FU modified miR-129 mimic as a novel therapeutic for non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1490.

10 November 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
APAmartya Pal
Amartya Pal
AOAnushka Ojha
Anushka Ojha
JYJohn Yuen
John Yuen
HBHersh Bendale
Hersh Bendale
LCLei Chen
Lei Chen
JJJingfang Ju
Jingfang Ju
Gemcitabine remains a mainstay of pancreatic ductal adenocarcinoma (PDAC) treatment, while the RAS(ON) inhibitor daraxonrasib has recently demonstrated improved survival in previously treated metastatic disease. However, acquired resistance to both therapies remains a major clinical challenge. Here, we developed MTX-5-FU-Gem-miR-15a, a multimodal microRNA (miRNA)-based therapeutic, by chemically modifying tumor-suppressive miR-15a with methotrexate (MTX), 5-fluorouracil (5-FU), and gemcitabine (Gem) to combine sequence specific gene regulation with disruption of nucleotide metabolism. MTX-5-FU-Gem-miR-15a exhibited low-nanomolar potency across five PDAC cell lines and retained activity in gemcitabine- and daraxonrasib-resistant models under vehicle-free conditions, substantially exceeding that of stoichiometrically matched free antimetabolites. Treatment induced S-phase accumulation, increased DNA damage and apoptosis, and suppressed checkpoint and survival-associated proteins, including WEE1, CHK1, YAP1, and BCL-2. Transcriptomic and proteomic analyses revealed increased DNA replication, replication-stress, and repair-associated programs, together with reduced oncogenic signaling. In gemcitabine-resistant cells, treatment restored the gemcitabine-activating enzyme dCK, reduced ABCC1 and ABCC3 expression, and suppressed resistance-associated signaling programs, indicating partial remodeling of resistance-associated pathways. MTX-5-FU-Gem-miR-15a also synergized with daraxonrasib (mean Bliss synergy score, 22.52) and activated tumor-cell-intrinsic STING-TBK1 signaling, accompanied by increased interferon stimulated gene expression and IFN-β and CXCL10 secretion. Finally, MTX-5-FU-Gem-miR-15a retained low-nanomolar potency in three patient-derived PDAC organoids and significantly suppressed metastatic tumor growth in vivo at 4 mg/kg. Together, these findings support a multimodal miRNA therapeutic strategy that combines replication-associated DNA damage, checkpoint protein suppression, and innate immune activation-associated responses to target therapeutic resistance in PDAC.

18 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
GHGa-Ram Hwang
Ga-Ram Hwang
JYJohn Yuen
John Yuen
AFAndrew Fesler
Andrew Fesler
HFHannah Farley
Hannah Farley
JHJohn D. Haley
John D. Haley
JJJingfang Ju
Jingfang Ju
Lung cancer is the leading cause of cancer-related deaths in the United States with non-small cell lung cancer (NSCLC) accounting for most cases. Despite advances in cancer therapeutics, the 5-year survival rate has remained poor due to several contributing factors, including its resistance to therapeutics. Therefore, there is a pressing need to develop therapeutics that can overcome resistance. Non-coding RNAs, including microRNAs (miRNAs), have been found to contribute to cancer resistance and therapeutics by modulating the expression of several targets involving multiple key mechanisms. In this study, we investigated the therapeutic potential of miR-129 modified with 5-fluorouracil (5-FU) in NSCLC. Our results show that 5-FU modified miR-129 (5-FU-miR-129) inhibits proliferation, induces apoptosis, and retains function as a miRNA in NSCLC cell lines A549 and Calu-1. Notably, we observed that 5-FU-miR-129 was able to overcome resistance to tyrosine kinase inhibitors and chemotherapy in cell lines resistant to erlotinib or 5-FU. Furthermore, we observed that the inhibitory effect of 5-FU-miR-129 can also be achieved in NSCLC cells under vehicle-free conditions. Finally, 5-FU-miR-129 inhibited NSCLC tumor growth and extended survival in vivo without toxic side effects. Altogether, our results demonstrate the potential of 5-FU-miR-129 as a highly potent cancer therapeutic in NSCLC.